Crossmark Global Holdings Inc. purchased a new position in shares of Diplomat Pharmacy, Inc. (NYSE:DPLO) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 25,970 shares of the company’s stock, valued at approximately $538,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Louisiana State Employees Retirement System increased its holdings in shares of Diplomat Pharmacy by 0.6% during the 2nd quarter. Louisiana State Employees Retirement System now owns 17,800 shares of the company’s stock worth $263,000 after buying an additional 100 shares during the last quarter. Capstone Asset Management Co. increased its holdings in shares of Diplomat Pharmacy by 0.5% during the 2nd quarter. Capstone Asset Management Co. now owns 24,430 shares of the company’s stock worth $362,000 after buying an additional 120 shares during the last quarter. Arizona State Retirement System increased its holdings in shares of Diplomat Pharmacy by 0.9% during the 2nd quarter. Arizona State Retirement System now owns 22,800 shares of the company’s stock worth $337,000 after buying an additional 200 shares during the last quarter. Bank of Montreal Can increased its holdings in shares of Diplomat Pharmacy by 3.0% during the 2nd quarter. Bank of Montreal Can now owns 11,600 shares of the company’s stock worth $172,000 after buying an additional 340 shares during the last quarter. Finally, Texas Permanent School Fund increased its holdings in shares of Diplomat Pharmacy by 1.5% during the 2nd quarter. Texas Permanent School Fund now owns 31,890 shares of the company’s stock worth $472,000 after buying an additional 470 shares during the last quarter. Institutional investors and hedge funds own 66.51% of the company’s stock.

A number of analysts have recently issued reports on DPLO shares. BidaskClub downgraded shares of Diplomat Pharmacy from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 17th. Needham & Company LLC restated a “buy” rating and set a $23.75 price target (up previously from $19.75) on shares of Diplomat Pharmacy in a report on Wednesday, October 4th. Robert W. Baird restated a “buy” rating and set a $20.00 price target on shares of Diplomat Pharmacy in a report on Sunday, September 17th. TheStreet upgraded shares of Diplomat Pharmacy from a “d+” rating to a “c-” rating in a report on Thursday, August 10th. Finally, Zacks Investment Research upgraded shares of Diplomat Pharmacy from a “sell” rating to a “hold” rating in a report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. Diplomat Pharmacy currently has an average rating of “Hold” and a consensus target price of $19.39.

TRADEMARK VIOLATION WARNING: “Crossmark Global Holdings Inc. Takes $538,000 Position in Diplomat Pharmacy, Inc. (DPLO)” was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.dailypolitical.com/2017/11/19/crossmark-global-holdings-inc-takes-538000-position-in-diplomat-pharmacy-inc-dplo.html.

Shares of Diplomat Pharmacy, Inc. (NYSE DPLO) opened at $15.00 on Friday. Diplomat Pharmacy, Inc. has a 1-year low of $12.25 and a 1-year high of $21.99. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.34 and a quick ratio of 0.82. The firm has a market cap of $1,033.09, a P/E ratio of 19.48, a P/E/G ratio of 2.70 and a beta of 0.74.

Diplomat Pharmacy (NYSE:DPLO) last posted its earnings results on Monday, November 6th. The company reported $0.25 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a net margin of 0.18% and a return on equity of 8.30%. The firm had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.16 billion. During the same quarter last year, the firm earned $0.21 EPS. The firm’s revenue for the quarter was down 4.8% on a year-over-year basis. equities analysts expect that Diplomat Pharmacy, Inc. will post 0.85 earnings per share for the current fiscal year.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.